Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIT-HF: Semaglutide vs Calorie-Restricted Diet in Obesity and HFrEF
NCT06423599Phase 3Recruiting
- Start
- Apr 2024
- Primary completion
- Dec 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in heart failure with reduced ejection fraction (HFrEF), obesity. Started Apr 2024; status: recruiting.
02
Drugs
03
Conditions
heart failure with reduced ejection fraction (HFrEF)obesity
Beyond the preview
Go deeper on NCT06423599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06423599.